Hemogram

The hemogram test is a basic laboratory analysis that evaluates the overall health status of the blood by measuring erythrocyte, leukocyte and platelet values. This test provides comprehensive and reliable information for the early diagnosis of infections, anemia and hematological disorders.

Hemogram parameter analysis offers important clues in distinguishing types of anemia by examining the volume and density characteristics of red blood cells. MCV, MCH and MCHC values help guide the diagnostic process and support treatment planning.

Hemogram leukocyte evaluation is used to show the status of the immune response. The distribution of leukocyte subtypes plays a critical role in determining the source of infections and monitoring inflammatory processes, thereby providing accurate clinical guidance.

Hemogram platelet examination provides important information about coagulation functions. Platelet count and volume are used in the evaluation of bleeding tendency or thrombotic risk and increase the safety of surgical planning and treatment processes.

What is a hemogram (complete blood count)?

Hemogram, that is, complete blood count, is a basic laboratory test that includes the measurement of many parameters in the blood such as red cells (erythrocytes), white cells (leukocytes), platelets and hemoglobin. It is used in the diagnosis and follow-up of infections, anemias, inflammatory diseases and hematological disorders. Because it is easy and quick to perform, it is frequently preferred in routine health check-ups.

What does the hemogram test measure?

You can think of this test as a kind of “census” that measures the number and characteristics of the three main cell groups in your circulation. This test evaluates both the quantity (how much is there?) and the quality (what do they look like?) of the main components in your blood.

This count is a starting point for understanding your body’s general health status. It plays a critical role in the diagnosis and follow-up of a wide range of conditions such as anemia, infections, immune system problems and even some blood diseases.

The process of taking a blood sample is quite simple; a small amount of blood, usually drawn from a vein in the arm, is placed into a small tube containing a special substance that prevents clotting.

So what does this test examine? The three main cell groups in our blood are:

• Red blood cells (erythrocytes)
• White blood cells (leukocytes)
• Platelets (thrombocytes)

Each of these three groups has a vital function in our body, and any change in their numbers can be a sign of an underlying health problem. The balance of these cells is one of the most basic indicators of how well the body is functioning.

Why are red blood cells (erythrocytes) and anemia so important?

Red blood cells are responsible for transporting oxygen, the most basic need of our body. These cells carry the oxygen they take from our lungs to tissues in even the most remote corners of our body and take up carbon dioxide, a waste product, and carry it back to the lungs to be excreted.

The hemogram test evaluates this oxygen-carrying capacity through three main parameters:

• Red Blood Cell Count (RBC): Shows the total number of red blood cells in a certain volume of your blood.
• Hemoglobin (Hgb): An iron-rich protein found inside red blood cells that binds oxygen and carries it. It is also the substance that gives blood its red color. The amount of hemoglobin in the blood is one of the most direct indicators of the body’s oxygen-carrying capacity.
• Hematocrit (Hct): Shows what percentage of your total blood volume is made up of red blood cells. For example, a hematocrit value of 40% means that 40 milliliters of every 100 milliliters of your blood consists of red blood cells.

These three values are closely related and are usually interpreted together. When these values are below normal, it is called anemia. Anemia causes the body not to receive enough oxygen and may lead to symptoms such as weakness, fatigue, easy tiring, pale skin and shortness of breath.

There can be many causes of anemia. Among the most common are nutritional deficiencies such as iron, vitamin B12 or folate, chronic diseases, blood loss or some genetic conditions.

Conversely, when these values are higher than normal (polycythemia or erythrocytosis), the blood becomes more viscous, that is, “thicker.” This can make it difficult for the blood to circulate through small vessels and increase the risk of clotting. Therefore, the balance of these three parameters is essential for overall health.

What details about anemia do hemogram values such as MCV, MCH and RDW explain?

The hemogram test does not only say “there is anemia”; it also provides very valuable clues about the cause of this anemia. It does this thanks to a series of calculated values known as “red blood cell indices.” These values provide detailed information about the average size, hemoglobin content and size distribution of red blood cells.

These indices draw a kind of road map in the diagnosis of anemia:

• MCV (Mean Corpuscular Volume): This value shows the average size or volume of a single red blood cell. It is the most important parameter used in classifying anemia.
• Low MCV (Microcytic Anemia): The cells are smaller than normal. This is most commonly seen in iron deficiency or thalassemia (Mediterranean anemia) carrier state.
• Normal MCV (Normocytic Anemia): The cells are normal in size. This is often seen in acute blood loss or anemias due to a chronic disease (such as kidney disease).
• High MCV (Macrocytic Anemia): The cells are larger than normal. This most often points to a vitamin B12 or folate deficiency.
• MCH and MCHC (Mean Corpuscular Hemoglobin and Mean Corpuscular Hemoglobin Concentration): These two values measure the amount and concentration of hemoglobin inside red blood cells. Simply put, they show how “red” or “pale” the cells are. Low MCHC (hypochromia) shows that the hemoglobin inside the cells has decreased and is a typical finding of iron deficiency anemia.
• RDW (Red Cell Distribution Width): This parameter measures the variability in the size of your red blood cell population. In other words, it shows whether the cells are “of various sizes” or “all the same size.”
• High RDW: Shows that there are marked size differences between cells. For example, in iron deficiency anemia the bone marrow gradually starts to produce smaller cells, and both the older normal-sized cells and the newer smaller cells are found together in the blood. This raises the RDW.
• Normal RDW: Shows that the cells are generally of uniform size. For example, in thalassemia carrier state, the cells are also small (MCV is low), but they tend to be uniformly small, so RDW is usually normal.

When these indices are evaluated together, they reveal not only whether there is anemia, but also largely the probable cause of this anemia. This allows additional tests that directly target the cause (such as iron supplementation or vitamin B12 testing) to be planned.

How do white blood cells (leukocytes) reflect the body’s defense status?

White blood cells (leukocytes) are the “defense army” of our body or the main soldiers of the immune system. Their duty is to recognize and destroy bacteria, viruses, fungi and other foreign invaders.

• Total White Blood Cell (WBC) Count: This value shows the total number of white blood cells in your blood.
• Leukocytosis (High WBC): This is usually a sign that the body is fighting an infection or inflammation. When the body senses a threat, it sends a signal to the bone marrow to “produce more soldiers” and the WBC count increases. Bacterial or viral infections are the most common causes. However, this elevation may also be related to medications (such as corticosteroids), extreme stress or more serious conditions.
• Leukopenia (Low WBC): Indicates that the body’s defense against infections has decreased. This may occur when the bone marrow cannot produce enough cells (as in some types of cancer or aplastic anemia), when the immune system attacks its own white cells (autoimmune diseases) or as a side effect of treatments such as chemotherapy.

However, the total count alone is not sufficient. The real detailed information comes from the “differential” (leukocyte formula) count, which shows which subtypes of this “army” it is composed of. This tells us which type of defense cell has increased or decreased, giving a clearer idea of the source of the problem.

What does “differential” (formula) in the hemogram test mean?

While the total white blood cell count tells us the “army’s” size, the differential count gives us the breakdown of the different types of soldiers (units) within this army. Each is specialized in a different type of enemy:

This army mainly consists of the following types of soldiers:

• Neutrophils
• Lymphocytes
• Monocytes
• Eosinophils
• Basophils

This breakdown can provide very specific clues as to what the problem is. For example, high neutrophil levels are a classic sign of bacterial infections. Neutrophils are the first response team against bacteria and fungi.

High lymphocyte levels (lymphocytosis), on the other hand, mostly point to viral infections (such as flu, common cold, mononucleosis). Lymphocytes are specialized in fighting viruses and in creating the immune system’s “memory” (antibody production).

High monocyte levels are often seen in chronic (long-term) infections, tuberculosis or some autoimmune diseases. High eosinophil levels (eosinophilia) most frequently increase in allergic reactions (asthma, hay fever) and parasitic infections. Basophils are seen more rarely and may play a role in severe allergic reactions.

When looking at this breakdown, it is important to focus on “absolute counts” rather than percentages. Because if the total count is very low, the percentage of a cell type may appear high, but its absolute count (the real number of fighters in the body) may actually be normal or low. Therefore, the absolute neutrophil count or absolute lymphocyte count is the most clinically meaningful information.

How do platelets affect bleeding and clotting?

Platelets are the smallest cell fragments in our blood and have a vital function: clotting. When we get a cut or a vessel is damaged, platelets are the first to rush to the area. They stick to the injured site, clump together to form a “platelet plug” and release chemicals that initiate the clotting process to stop the bleeding.

• Platelet Count (PLT): Measures the total amount of platelets in your blood.
• Thrombocytopenia (Low Platelets): Platelet count below normal. This reduces the blood’s ability to clot and increases the risk of bleeding. It can lead to easy bruising, small red-purple spots (petechiae) or, in more severe cases, internal bleeding. Causes include insufficient production in the bone marrow, the immune system destroying platelets (as in ITP) or some medications.
• Thrombocytosis (High Platelets): Platelet count above normal. This increases the tendency of the blood to clot unnecessarily and raises the risk of thrombosis (vessel occlusion). These clots may cause serious problems in the legs (deep vein thrombosis), lungs (pulmonary embolism), brain (stroke) or heart (heart attack).
• MPV (Mean Platelet Volume): Just like MCV in red blood cells, MPV shows the average size of platelets. Generally, larger platelets are “younger” and metabolically more “active.” When the need for platelets increases (for example when platelets are rapidly consumed), the bone marrow releases larger and younger platelets into circulation. Therefore, MPV provides indirect information about the rate of platelet production and activity.

Why is the hemogram test so critical before starting IVF treatment?

IVF treatment is an intense process both physically and emotionally. As you enter this process, it is very important to ensure that your body is ready for this journey. At this point, the hemogram test comes into play as a kind of “health report card” showing the candidate’s general health status.

The main purpose of this test is to perform a comprehensive health screening before starting treatment and to ensure that the mother-to-be enters the procedures and the subsequent pregnancy in the best possible condition. This is a form of “proactive risk management.”

This blood count performed before treatment provides a critical “reference point” (baseline) for comparing any changes that may appear later during treatment or pregnancy.

The greatest value of this test lies in its ability to detect hidden health problems at the very beginning that may jeopardize treatment success or safety:

• Detection of Anemia: If moderate anemia is detected, it can be corrected before starting treatment.
• Detection of Infection: A high WBC count may indicate a hidden infection in the body. Starting an IVF process without treating this infection may prevent embryo implantation.
• Platelet Problems: A low platelet count (thrombocytopenia) increases the risk of bleeding during the egg retrieval procedure (OPU). Knowing this in advance allows the necessary precautions to be taken.

The results of this test are usually considered valid for three months. This period is not arbitrary; it is consistent with both the approximately 120-day lifespan of red blood cells and the physiology of the final maturation phase (about 3 months) of the eggs targeted in an IVF cycle. This ensures that the test accurately reflects your metabolic status during the critical period when treatment will take place.

How do anemia and iron deficiency hinder IVF success?

Perhaps the most critical role of the hemogram test in the IVF process is to detect anemia and, in particular, iron deficiency anemia. This condition not only affects overall health, but also has a direct and strong impact on fertility and IVF success.

Many scientific studies have shown a clear relationship between anemia and poor reproductive outcomes. When the body does not have enough iron and hemoglobin, sufficient oxygen cannot be delivered to the tissues. The ovaries and uterus are metabolically very active organs and need a large amount of oxygen to function properly.

Oxygen deficiency (hypoxia) can disrupt the most fundamental stages of the reproductive process.

• Egg (oocyte) quality
• Fertilization rates
• Embryo development
• Preparation of the uterine lining (endometrium)

So iron deficiency not only makes you feel tired, it can also directly affect the ovary’s capacity to produce healthy eggs. In women with iron deficiency, it has been reported that egg quality obtained during IVF treatment is decreased, fertilization rates are reduced and the likelihood of obtaining “top-quality” embryos is lower.

These negative effects continue throughout the process. Low hemoglobin and iron levels have been associated with implantation failure, a higher miscarriage rate and, even if pregnancy is achieved, poor pregnancy outcomes such as preterm birth or low birth weight.

The good news is that this is a modifiable risk factor. It has been shown that treating iron deficiency significantly improves reproductive outcomes.

Why is timing in iron deficiency treatment vital for IVF success?

When anemia is detected, the first thought is often “let’s start iron treatment immediately.” However, research has shown that when it comes to IVF success, the timing of treatment is as important as the treatment itself.

The scientific data on this are very clear. Iron supplements given just before starting ovarian stimulation treatment for IVF or during the treatment itself have not been shown to significantly improve egg or embryo quality in that specific cycle.

Why? Because the “quality journey” of that egg had started long before those injections began.

In contrast, a striking finding is that in patients who received iron deficiency treatment and then waited at least two months before starting ovarian stimulation, egg fertilization rates and embryo quality returned to the levels seen in healthy control groups without iron deficiency.

This finding provides a very valuable physiological insight into the development of the human egg (folliculogenesis). The final maturation stages of an egg before it is ready to be collected in IVF begin approximately 2–3 months earlier.

This “two-month waiting period” needed for the beneficial effects of iron to appear strongly suggests that iron exerts its effects not in the final weeks of the egg’s development, but in this early and critical maturation window.

This is information that fundamentally changes the clinical approach. The goal should not only be to “correct anemia,” but to “correct anemia and then wait long enough for the eggs to benefit from this improvement.” This requires that the IVF treatment schedule be strategically planned in the way that best fits the patient’s own ovarian physiology.

What are inflammatory markers such as NLR and PLR in the hemogram?

The successful implantation of an embryo into the uterine lining is an extremely complex biological event. This process requires a delicate balance between the embryo and the prospective mother’s immune system. For successful implantation, a “controlled local inflammation” in the uterus is necessary; at the same time, the mother’s immune system must not reject the embryo, which it may perceive as “foreign” because half of its genetic material comes from the father, and must instead develop “tolerance” toward it.

If there is a general (systemic) inflammatory state in the body, this delicate balance can be disrupted. An excessive immune response may turn the uterus into a “hostile” environment for the embryo, preventing implantation or leading to early miscarriages.

A simple hemogram test offers some calculated ratios that can provide indirect information about this systemic inflammatory status.

• NLR (Neutrophil-to-Lymphocyte Ratio): Obtained by dividing the absolute neutrophil count by the absolute lymphocyte count in the white blood cell differential.
• PLR (Platelet-to-Lymphocyte Ratio): Calculated by dividing the total platelet count by the absolute lymphocyte count.

When these ratios are higher than normal, they are considered indicators of low-grade chronic inflammation or immune system activation in the body.

Can NLR and PLR ratios really predict IVF failure?

The role of these ratios in predicting IVF success has been extensively studied in recent years, but a clear conclusion has not yet been reached. The scientific literature contains conflicting results on this subject.

Some studies have found a relationship between high NLR and PLR ratios and poor IVF outcomes (such as increased miscarriage risk). However, many other well-designed studies have not found a significant association between these pre-treatment values and IVF success rates (pregnancy or live birth). These studies have concluded that these ratios are not effective tools for predicting success.

These conflicting data show that these markers cannot be universally used as “predictors of success” or “indicators of failure.” The likely reason is that an “optimal” immune balance is required for implantation. A very low ratio may show that the immune system is too passive to initiate the “controlled inflammation” necessary for implantation; a very high ratio, on the other hand, may indicate an immune response that is aggressive enough to reject the embryo.

This “optimal” range probably varies from person to person and is affected by many factors such as the underlying cause of infertility.

Therefore, in current practice, these ratios are not standalone decision-making tools. However, values that are far outside the normal range may be a “trigger” to investigate whether there is an underlying treatable immune or inflammatory problem.

How does the platelet count determine safety risks in the IVF process?

The platelet count is one of the most critical parameters in the hemogram test in terms of the “safety” of the IVF process. This parameter plays a key role in managing two opposing risks: bleeding and clotting.

• Bleeding risk during Egg Retrieval (OPU)
• Risk of clotting (thrombosis) in OHSS (Ovarian Hyperstimulation Syndrome)

If the platelet count is very low (thrombocytopenia), the tendency to bleed increases during invasive procedures such as egg retrieval. Managing this risk requires close collaboration between the reproductive endocrinology specialist and a hematologist. If necessary, special treatments can be administered before the procedure to raise the platelet count to a safe level.

On the other hand, in Ovarian Hyperstimulation Syndrome (OHSS), an important complication of IVF treatment, the risk of clotting increases. In severe OHSS, fluid leaks from the vessels into body cavities. This leads to “hemoconcentration,” that is, thickening of the blood in the circulation. Thickened blood predisposes to clot formation (thrombosis). Even if the patient’s platelet count is within the normal range, the risk of clotting increases in this thickened blood. Therefore, in patients who develop severe OHSS, preventive blood thinners (anticoagulants) may be started to prevent this dangerous complication.

What is FNAIT (low platelet count in the baby) and is it related to IVF?

This is a much rarer but highly specialized aspect of platelets in relation to the IVF process. Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a serious immune problem that occurs during pregnancy.

Simply put, this is a type of “blood incompatibility,” but it occurs through platelets rather than red blood cells (as in Rh incompatibility).

The baby inherits a platelet antigen (protein structure) from the father that the mother does not have. The mother’s immune system perceives this “different” platelet antigen in the baby as foreign and produces antibodies against it. These antibodies cross the placenta, attack the baby’s platelets and destroy them.

This leads to severe thrombocytopenia in the fetus or newborn. Its most feared complication is intracranial hemorrhage, which can cause permanent neurological damage or death.

Historically, FNAIT was usually diagnosed reactively, after the first affected baby was born. However, IVF and genetic technologies offer a unique opportunity to proactively prevent this condition.

Especially for couples with a previous history of a baby with FNAIT, embryos developed in the laboratory can be genetically examined by the method of Preimplantation Genetic Diagnosis (PGD/PGT) before being transferred to the uterus. Embryos that carry a platelet antigen that will not trigger the mother’s immune system, that is, that are “compatible,” can be selected.

Transferring a compatible embryo prevents the mother’s immune system from being triggered from the outset and completely prevents the occurrence of FNAIT in that pregnancy.

How should hemogram results be handled for a healthy IVF journey?

As we have seen, a simple complete blood count (hemogram) is much more than just a safety check for a couple embarking on an IVF journey. This test is a basic “road map” that reveals your body’s biological readiness, hidden nutritional deficiencies that may affect egg quality, inflammatory states that may make implantation difficult, and bleeding or clotting risks that may jeopardize the treatment process.

Correctly interpreting these results and taking the necessary steps is one of the first and most important measures to maximize the chance of success.

Therefore, the following points are particularly important in the IVF process:

• Performing a hemogram as a comprehensive initial screening
• Investigating the cause of anemia (iron, B12, etc.) if detected
• Effectively replenishing iron stores if iron deficiency is present
• Waiting (at least 2 months) after iron treatment for egg quality to benefit
• Taking high white blood cell (WBC) counts seriously
• Treating underlying infections or inflammatory conditions
• Ensuring that platelet counts are at a safe level for egg retrieval
• Closely monitoring the coagulation profile if there is a risk of OHSS

Frequently Asked Questions